

Adenosine derivatives as antioxidant agents: synthesis, characterization, *in vitro* activity and theoretical insights.

Francisco Valdes², Nelson Brown³, Alejandro Morales-Bayuelo⁴, Luis Prent-Peñaloza¹, Margarita Gutierrez²

¹ Organic Synthesis Laboratory and Biological Activity (LSO-Act-Bio), PhD Applied Sciences, faculty of Engineering and Institute of Chemistry of Natural Resources, Universidad de Talca, Casilla 747, Talca 3460000, Chile. luisprent@gmail.com

² Organic Synthesis Laboratory and Biological Activity (LSO-Act-Bio), PhD sciences mention investigation and development of bioactive products, Institute of Chemistry of Natural Resources, Universidad de Talca, Casilla 747, Talca 3460000, Chile. franciscovaldesz@hotmail.es

³ Center for Medical Research, University of Talca School of Medicine, 3460000 Talca, Chile; Programa de Investigación Asociativa en Cáncer Gástrico (PIA-CG), Universidad de Talca. nbrown@utalca.cl

⁴ Centro de Investigación de Procesos del Tecnológico Comfenalco (CIPTEC), programa de Ingeniería Industrial, Fundación Universitaria Tecnológico Comfenalco – Cartagena, Cr 44 D N 30A, 91, Cartagena-Bolívar, 130001 Colombia. alejandromoraba@hotmail.com

SUPPLEMENTARY MATERIAL

CONTENTS

Figure S1. IR, ¹H and ¹³C nuclear magnetic resonance (NMR) spectra of compound **1a**.....3

Figure S2. IR, ¹H and ¹³C nuclear magnetic resonance (NMR) spectra of compound **1b**.....4

Figure S3. IR, ¹H and ¹³C nuclear magnetic resonance (NMR) spectra of compound **1c**.....5


Figure S4. IR, ¹H and ¹³C nuclear magnetic resonance (NMR) spectra of compound **2**.....6

Figure S5. IR, ¹H and ¹³C nuclear magnetic resonance (NMR) spectra of compound **3**.....7


Figure S6. IR, ¹H and ¹³C nuclear magnetic resonance (NMR) spectra of compound **4**.....8

Figure S7. IR, ¹H and ¹³C nuclear magnetic resonance (NMR) spectra of compound **5**.....9

Figure S1. Compound 1a: 2-(6-butylamino-purin-9-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol
IR (KBr):



¹H-RMN (DMSO-d₆, 400MHz)



¹³C-RMN (DMSO-d₆, 100 MHz)






Figure S2. Compound 1b: 2-[6-(5-amino-2-methyl-pentylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydrofuran-3,4-diol

IR (KBr):



¹H-RMN (DMSO-d₆, 400 MHz)



¹³C-RMN (DMSO-d₆, 100 MHz)






Figure S3. Compound 1c: 2-[6-(3-propylamino)-purin-9-yl]-5-hydroxymethyl-tetrahydro-furan-3,4-diol
IR (KBr):



¹H-RMN (DMSO-d₆, 400 MHz)



¹³C-RMN (DMSO-d₆, 100 MHz)






Figure S4. Compound 2: [6-(6-Chloro-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxol-4-yl]-methanol

IR (KBr):



¹H-RMN (DMSO-d₆, 400 MHz)



¹³C-RMN (DMSO-d₆, 100 MHz)






Figure S5. Compound 3: 6-(6-Chloro-purin-9-yl)-2,2-dimethyl-tetrahydro-furo[3,4-d][1,3]dioxole-4-carboxylic acid

IR (KBr):



¹H-RMN (DMSO-d₆, 400 MHz)



¹³C-RMN (DMSO-d₆, 100 MHz)






Figure S6. Compound 4: *1'-deoxy-1'-(6-chloro-9H-purin-9-yl)-β-D-ribofuranuronic acid*

IR (KBr):



¹H-RMN (DMSO-d₆, 400 MHz)



¹³C-RMN (DMSO-d₆, 100 MHz)






Figure S7. Compound 5: 6 - [(4-amino-2,3,5-triazole) thio] - β -D-ribofuranosyl-9H-purine-5'-N-ethyluronamide

IR (KBr):



¹H-RMN (DMSO-d₆, 400 MHz)



¹³C-RMN (DMSO-d₆, 100 MHz)

